In another small series of 23 patients with endocrine unresponsive and HER2-overexpressing tumours, Topo2α amplification correlated with a significantly high probability of achieving pCR after neo-adjuvant, anthracycline-based chemotherapy (Orlando et al, 2008). The gene discussed is ERBB2; the disease is neoplasm.